期刊
CURRENT OPINION IN ONCOLOGY
卷 33, 期 6, 页码 635-641出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0000000000000780
关键词
acute myeloid leukaemia; allogeneic stem cell transplant; immune-based therapies; refractory; relapsed; targeted therapy
类别
Treating patients with relapsed or refractory acute myeloid leukaemia has been a challenging task for many years, with the only potential curative option being allogeneic bone marrow transplantation. Recent advances in targeting molecular abnormalities with new agents offer a less toxic alternative to conventional chemotherapy, potentially serving as a bridge to transplantation. Ongoing clinical trials will shed light on the future prospects for these patients.
Purpose of review The treatment of patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) has been an unequal challenge for many decades. Although significant progress has been made in the discovery of the mechanisms underlying the molecular pathogenesis of the disease, more than 50% of AML patients still die, mostly from relapsed disease. Currently, the only potential curative option for patients with R/R AML remains allogeneic bone marrow transplantation in second complete remission, which is far being easy to achieve, mainly for patients with primary induction failure or older than 65 years. The purpose of this review is to discuss recent advances in the management of patients with R/R AML, with particular emphasis to new therapeutic options that are replacing conventional salvage chemotherapy. Recent findings The development of new agents selectively targeting molecular abnormalities offer more effective and less toxic alternative to chemotherapy, potentially useful as a bridge to allogeneic stem cell transplantation in second complete remission. The recent approval of new drugs for R/R is transforming the paradigm of care we have relied on for the past 50 years. Ongoing clinical trials will tell us how bright is the future for R/R AML patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据